Efficacy of probiotic supplements on Parkinson's disease: A systematic review and meta-analysis

IF 3.5 3区医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Complementary therapies in medicine Pub Date : 2024-05-04 DOI:10.1016/j.ctim.2024.103045

Xiaxia Jin , Wendi Dong , Kaile Chang , Yongmei Yan , Xiaochun Liu

{"title":"Efficacy of probiotic supplements on Parkinson's disease: A systematic review and meta-analysis","authors":"Xiaxia Jin , Wendi Dong , Kaile Chang , Yongmei Yan , Xiaochun Liu","doi":"10.1016/j.ctim.2024.103045","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to evaluate the clinical efficacy and safety of probiotics supplementation in the treatment of Parkinson's disease (PD).</p></div><div><h3>Methods</h3><p>We searched China National Knowledge Infrastructure (CNKI), Weipu (VIP) database, Wanfang Database, Sinomed (CBM), PubMed, Embase, Cochrane library and Web of Science databases for eligible studies from inception to January 4th, 2024. Randomized controlled trials (RCTS) comparing the effects of probiotic supplements and placebo in patients with PD. Meta-analysis was conducted with the software Review Manager 5.4. The quality assessment was performed according to Cochrane risk of bias tool.</p></div><div><h3>Results</h3><p>A total of 11 RCTs with 756 PD patients were included in this study. We found that probiotics could increase the number of complete bowel movements (CBMs) per week and improved the scores of Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) (SMD = 0.73, 95 % CI: 0.54 to 0.92, <em>P</em> < 0.00001, I<sup>2</sup> = 45 %; SMD = − 0.79, 95 % CI: − 1.19 to − 0.39, <em>P</em> < 0.001, I<sup>2</sup> = 55 %, respectively) compared with the placebo group. However, there was no significant difference between the two groups in improving fecal traits and defecation efforts in PD patients (SMD = 0.87, 95 % CI: 0.01 to 1.74<em>, P =</em> 0.05, I<sup>2</sup> = 94 %; SMD <em>=</em> 1.24, 95 % CI: − 1.58 to 4.06, <em>P ></em> 0.05, I<sup>2</sup> = 98 %, respectively). In terms of PD composite scale scores: after treatment, there was no significant difference in Movement Disorder Society-Unified-Parkinson Disease Rating Scale Ⅲ score (MDS-UPDRSⅢ) between the probiotic group and the placebo group (SMD = − 0.09, 95 % CI: − 0.35 to 0.16, <em>P</em> > 0.05, I<sup>2</sup> = 0 %).</p></div><div><h3>Conclusions</h3><p>In conclusion, based on the overall results of the available RCTs studies, our results suggested the potential value of probiotics in improving constipation symptoms in PD patients. Therefore, probiotics may be one of the adjuvant therapy for PD-related constipation patients. The findings of this study provide more proof supporting the effectiveness of probiotics, encouraging probiotics to be utilized alone or in combination with other therapies in clinical practice for PD patients. However, more well-designed RCTs with large sample sizes are required.</p></div>","PeriodicalId":10545,"journal":{"name":"Complementary therapies in medicine","volume":"82 ","pages":"Article 103045"},"PeriodicalIF":3.5000,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0965229924000335/pdfft?md5=8f897457b38db8cc86e0e44c6988fc39&pid=1-s2.0-S0965229924000335-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Complementary therapies in medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0965229924000335","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study aimed to evaluate the clinical efficacy and safety of probiotics supplementation in the treatment of Parkinson's disease (PD).

Methods

We searched China National Knowledge Infrastructure (CNKI), Weipu (VIP) database, Wanfang Database, Sinomed (CBM), PubMed, Embase, Cochrane library and Web of Science databases for eligible studies from inception to January 4th, 2024. Randomized controlled trials (RCTS) comparing the effects of probiotic supplements and placebo in patients with PD. Meta-analysis was conducted with the software Review Manager 5.4. The quality assessment was performed according to Cochrane risk of bias tool.

Results

A total of 11 RCTs with 756 PD patients were included in this study. We found that probiotics could increase the number of complete bowel movements (CBMs) per week and improved the scores of Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) (SMD = 0.73, 95 % CI: 0.54 to 0.92, P < 0.00001, I² = 45 %; SMD = − 0.79, 95 % CI: − 1.19 to − 0.39, P < 0.001, I² = 55 %, respectively) compared with the placebo group. However, there was no significant difference between the two groups in improving fecal traits and defecation efforts in PD patients (SMD = 0.87, 95 % CI: 0.01 to 1.74, P = 0.05, I² = 94 %; SMD = 1.24, 95 % CI: − 1.58 to 4.06, P > 0.05, I² = 98 %, respectively). In terms of PD composite scale scores: after treatment, there was no significant difference in Movement Disorder Society-Unified-Parkinson Disease Rating Scale Ⅲ score (MDS-UPDRSⅢ) between the probiotic group and the placebo group (SMD = − 0.09, 95 % CI: − 0.35 to 0.16, P > 0.05, I² = 0 %).

Conclusions

In conclusion, based on the overall results of the available RCTs studies, our results suggested the potential value of probiotics in improving constipation symptoms in PD patients. Therefore, probiotics may be one of the adjuvant therapy for PD-related constipation patients. The findings of this study provide more proof supporting the effectiveness of probiotics, encouraging probiotics to be utilized alone or in combination with other therapies in clinical practice for PD patients. However, more well-designed RCTs with large sample sizes are required.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

益生菌补充剂对帕金森病的疗效：系统回顾与荟萃分析。

目的：本研究旨在评估补充益生菌治疗帕金森病（PD）的临床疗效和安全性：本研究旨在评估补充益生菌治疗帕金森病（PD）的临床疗效和安全性：方法：我们检索了中国国家知识基础设施（CNKI）、维普（VIP）数据库、万方数据库、Sinomed（CBM）、PubMed、Embase、Cochrane图书馆和Web of Science数据库中从开始到2024年1月4日符合条件的研究。比较益生菌补充剂和安慰剂对帕金森病患者疗效的随机对照试验（RCTS）。使用Review Manager 5.4软件进行元分析。根据Cochrane偏倚风险工具进行质量评估：本研究共纳入了 11 项 RCT，共 756 名帕金森病患者。我们发现，与安慰剂组相比，益生菌可增加每周完全排便（CBM）的次数，并改善患者便秘生活质量评估问卷（PAC-QOL）的评分（SMD = 0.73，95% CI：0.54 - 0.92，P < 0.00001，I2 = 45%；SMD = -0.79，95% CI：-1.19 - 0.39，P < 0.001，I2 = 55%）。然而，两组在改善帕金森病患者粪便性状和排便力度方面没有明显差异（SMD = 0.87，95% CI：0.01 - 1.74，P = 0.05，I2 = 94%；SMD = 1.24，95% CI：-1.58 - 4.06，P > 0.05，I2 = 98%）。在帕金森病综合量表评分方面：治疗后，益生菌组与安慰剂组的运动障碍协会-统一帕金森病评分量表Ⅲ（MDS-UPDRSⅢ）评分无显著差异（SMD = -0.09，95% CI：-0.35 - 0.16，P > 0.05，I2 = 0%）：总之，根据现有RCT研究的总体结果，我们的研究结果表明益生菌在改善PD患者便秘症状方面具有潜在价值。因此，益生菌可能是治疗与帕金森病相关的便秘患者的辅助疗法之一。这项研究结果为益生菌的有效性提供了更多证据，鼓励在临床实践中对帕金森病患者单独使用益生菌或将其与其他疗法结合使用。不过，还需要更多设计合理、样本量大的研究试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Complementary therapies in medicine 医学-全科医学与补充医学

CiteScore

8.60

自引率

2.80%

发文量

101

审稿时长

112 days

期刊介绍： Complementary Therapies in Medicine is an international, peer-reviewed journal that has considerable appeal to anyone who seeks objective and critical information on complementary therapies or who wishes to deepen their understanding of these approaches. It will be of particular interest to healthcare practitioners including family practitioners, complementary therapists, nurses, and physiotherapists; to academics including social scientists and CAM researchers; to healthcare managers; and to patients. Complementary Therapies in Medicine aims to publish valid, relevant and rigorous research and serious discussion articles with the main purpose of improving healthcare.